The Journal of Practical Medicine >

2026 , Vol. 42 >Issue 3: 470 - 476

DOI: https://doi.org/10.3969/j.issn.1006-5725.2026.03.015

Treatise: Clinical Practice

Analysis of immunophenotypic and genetic in pediatric acute megakaryoblastic leukemia

  • Ke'an JIANG ,
  • Guo FU ,
  • Wanqing LI ,
  • Yi SHU ,
  • Yuanyuan CHEN ,
  • Qin MOU ,
  • Xianmin GUAN
Expand
  • 1.Center of Clinical Molecular Medicine，Children′s Hospital of Chongqing Medical University，National Clinical Research Center for Children and Adolescents' Health and Diseases，Ministry of Education Key Laboratory of Child Development and Disorders，Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases，Chongqing 400014，Chongqing，Chin
    a2Department of Hematology and Oncology，Children′s Hospital of Chongqing Medical University，National Clinical Research Center for Children and Adolescents' Health and Diseases，Ministry of Education Key Laboratory of Child Development and Disorders，Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases，Chongqing 400014，Chongqing，China

Received date: 2025-10-28

  Online published: 2026-02-09

Fold

Abstract

Objective To analyze the immunophenotypic and genetic characteristics of children with acute megakaryoblastic leukemia （AMKL） and provide relevant evidence for clinical diagnosis and treatment. Methods A retrospective analysis was conducted on the clinical data of 45 children with AMKL who were admitted to the hospital from September 2017 to December 2024， including 23 males and 22 females. Among them， 7 cases were Down syndrome-associated AMKL （DS-AMKL）， and 38 cases were non-DS-AMKL. Flow cytometry was used for immunophenotypic analysis， G-banding for karyotype analysis， and RT-PCR and sequencing for fusion gene detection. Results The most common clinical manifestation of AMKL children at initial diagnosis was skin ecchymosis or petechiae， with a median platelet count of 17（3 ~ 222）× 109/L. All children expressed at least one of the platelet-associated glycoproteins CD41a， CD42b， or CD61 in bone marrow blasts， with CD41a having the highest expression rate （84.4%）. Compared to non-DS-AMKL， DS-AMKL children had significantly higher detection rates of CD7， CD13， and CD36 （P < 0.05）， while CD41a had a significantly higher detection rate in non-DS-AMKL （P < 0.05）. Karyotype analysis was performed in 41 children， and chromosomal abnormalities were detected in 33 cases （80.5%）， including 14 cases （34.1%） with complex karyotypes. Fusion gene testing was performed in 21 non-DS-AMKL children， revealing 6 cases of CBFA2T3：：GLIS2， 2 cases of NUP98：：KDM5A， and 1 case each of NUP98：：ING4， RBM15：：MKL1， and KMT2A：：MLLT3. Children positive for CBFA2T3：：GLIS2 exhibited a characteristic immunophenotype， with high expression of CD56 and no expression of HLA-DR or CD36. Conclusions Pediatric AMKL is a highly heterogeneous disease with relatively characteristic immunophenotypes， a high rate of chromosomal abnormalities， and CBFA2T3：：GLIS2 being the most common fusion gene. Immunophenotypic and genetic molecular testing and analysis can improve the diagnosis and identification of AMKL， enabling better prognostic stratification and treatment selection.

Key words： acute megakaryoblastic leukemia; immunophenotype; chromosomes; fusion genes

Cite this article

Ke'an JIANG , Guo FU , Wanqing LI , Yi SHU , Yuanyuan CHEN , Qin MOU , Xianmin GUAN . Analysis of immunophenotypic and genetic in pediatric acute megakaryoblastic leukemia[J]. The Journal of Practical Medicine, 2026 , 42(3) : 470 -476 . DOI: 10.3969/j.issn.1006-5725.2026.03.015

References

[1] DIMA D， OPRITA L， ROSU A M， et al. Adult acute megakaryoblastic leukemia：rare association with cytopenias of undetermined significance and p210 and p190 BCR- ABL transcripts［J］. Onco Targets Ther， 2017， 10（1）：5047-5051.doi：10.2147/OTT.S146973 .
[2] KYOGO S， ASAHITO H， YUSUKE O， et al. A retrospective analysis of gene fusions and treatment outcomes in pediatric acute megakaryoblastic leukemia without Down syndrome［J］. Haematologica， 2024， 109（6）：1936-1940.doi：10.3324/haematol. 2023. 283760 .
[3] WANG L， PETERS J M， FUDA F， et al. Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype［J］. Cytometry B Clin Cytom， 2015， 88（4）：244-252.doi：10.1002 /cyto.b.21198 .
[4] JOSEPH G， AIDA C， PRABAKARAN P， et al. Acute megakaryoblastic leukemia with trisomy 3 and CBFA2T3：：GLIS2： A case report［J］. Genes Chromosomes Cancer， 2022， 61（8）：491-496. doi：10.1002/ gcc.23039 .
[5] BROUWER N， MATARRAZ S， NIERKENS S， et al. Immunophenotypic analysis of acute megakaryoblastic leukemia： A EuroFlow Study［J］. Cancers（Basel）， 2022， 14（6）：1583-1598. doi：10.3390/cancers14061583 .
[6] HASLE H， FRIEDMAN J M， OLSEN J H， et al. Low risk of solid tumors in persons with Down syndrome［J］. Genet Med， 2016， 18（11）：1151-1157.doi：10.1038/gim.2016.23 .
[7] MAAROUF N， MAHMOUD S， KHEDR R， et al. Outcome of childhood acute megakaryoblastic leukemia： Children′s Cancer Hospital Egypt 57357 experience［J］. Clin Lymphoma Myeloma Leuk， 2019， 19（3）：142-152.doi：10.1016/j.clml.2018.12.011 .
[8] PINTO C M， BERTOLUCCI C M， SEVERINO A R， et al. Immunophenotypic markers for the evaluation of minimal/measurable residual disease in acute megakaryoblastic leukemia［J］. Hematol Transfus Cell Ther， 2023， 46（4）：542-548. doi：10.1016/j.htct. 2023.09.2364 .
[9] KOSMIDOU A， TRAGIANNI A， Gavriilaki E. Myeloid leukemia of Down Syndrome［J］.Cancers （Basel）， 2023， 15（13）：1-13.doi：10.3390/cancers15133265 .
[10] MCNULTY M， CRISPINO J D.Acute megakaryocytic leukemia［J］.Cold Spring Harb Perspect Med，2020，10（2）：1-16.doi：10.1101/cshperspect.a034884 .
[11] DE ROOIJ J D， MASETTI R， WAN DEN HEUVEL-EIBRINK M M， et al. Recurrent abnormalities can be used for risk group stratification in pediatric AMKL： A retrospective intergroup study［J］. Blood， 2016， 127（26）：3424-3430.doi：10.1182/blood-2016-01-695551 .
[12] MARCHI F D， ARAKI M， KOMATSU N. Molecular features， prognosis， and novel treatment options for pediatric acute megakaryoblastic leukemia［J］. Expert Rev Hematol， 2019， 12（5）：285-293.doi：10. 1080/17474086.2019.1609351 .
[13] SAVASAN S， BUCK S， RAIMONDI S C， et al. CD36 （thrombospondin receptor） expression in childhood acute megakaryoblastic leukemia： In vitro drug sensitivity and outcome［J］. Leuk Lymphoma， 2006， 47（10）：2076-2083.doi：10.1080/10428190600773180 .
[14] KHANLARI M， WANG L， BOLEN C Y， et al. CBFA2T3：：GLIS2-positive acute leukemia with RAM and mixed T/megakaryocytic phenotype［J］. EJHaem， 2023， 4（3）：765-769.doi：10.1002/jha2.741 .
[15] SMITH J L， RHONDA E R， MARIANNE T S， et al. Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options-A COG and target pediatric AML study［J］. Clin Cancer Res， 2020， 26（3）：726-737.doi：10.1158/1078-0432.CCR-19-1800 .
[16] DASTUGUE N， LAFAGE-POCHITALOFF M， PAGES M， et al.Cytogenetic profile of childhood and adult megakaryoblastic leukemia （M7）： A study of the Groupe Fran?ais de Cytogénétique Hématologique （GFCH）［J］. BLOOD， 2002， 100（2）：618-626.doi：10.1182/blood-2001-12-0241 .
[17] HARA Y， SHIBA N， OHKI K， et al. Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down Syndrome［J］. Genes Chromosomes Cancer， 2017， 56（5）：394-404. doi：10.1002/gcc.22444 .
[18] QI H X， MAO Y， CAO Q， et al. Clinical characteristics and prognosis of 27 patients with childhood acute megakaryoblastic leukemia［J］. Med Sci Monit， 2020， 26：e922622.doi：10.12659/MSM.922662 .
[19] LI J X， MAGGIE L， KALEV-ZYLINSKA M L. Advances in molecular characterization of pediatric acute megakaryoblastic leukemia not associated with Down syndrome：Impact on therapy development［J］. Front Cell Dev Biol， 2023， 11：1-20.doi：10.3389/fcell.2023.1170622 .
[20] DE ROOIJ J D， BRANSTETTER C， MA J， et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes［J］. Nat Genet， 2017， 49（3）：451 -456.doi：10.1038/ng.3772 .
Options
Outlines

/

〈 〉